Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipul Jain

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Neuromuscular Disorders : NMD|February 6, 2026
Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL studyStephan Wenninger, Hani Kushlaf, Noemi Hummel, et al.
The Journal of Allergy and Clinical Immunology|September 12, 2022
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticariaMarcus Maurer, William Berger, Ana Giménez-Arnau, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2023
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Ana Giménez-Arnau, Koremasa Hayama, et al.
Dermatology and Therapy|May 24, 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck RegionKilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2025
Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION studyJulie McLaren, Yun Chon, Kevin S Gorski, et al.
Journal of Cutaneous Medicine and Surgery|September 30, 2021
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort StudyAbrahim Abduelmula, Jorge R Georgakopoulos, Asfandyar Mufti, et al.
Journal of Cutaneous Medicine and Surgery|November 13, 2025
Real-World Treatment Philosophies in Managing Atopic Dermatitis and Psoriasis: A Canadian Dermatologist SurveyJennifer Beecker, Chih-Ho Hong, Mark G Kirchhof, et al.
Therapeutic Advances in Rare Disease|February 3, 2026
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trialsHenning Andersen, Jordi Díaz-Manera, Ozlem Goker-Alpan, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Neuromuscular Disorders : NMD|February 6, 2026
Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL studyStephan Wenninger, Hani Kushlaf, Noemi Hummel, et al.
The Journal of Allergy and Clinical Immunology|September 12, 2022
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticariaMarcus Maurer, William Berger, Ana Giménez-Arnau, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2023
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Ana Giménez-Arnau, Koremasa Hayama, et al.
Dermatology and Therapy|May 24, 2026
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck RegionKilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2025
Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION studyJulie McLaren, Yun Chon, Kevin S Gorski, et al.
Journal of Cutaneous Medicine and Surgery|September 30, 2021
Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort StudyAbrahim Abduelmula, Jorge R Georgakopoulos, Asfandyar Mufti, et al.
Journal of Cutaneous Medicine and Surgery|November 13, 2025
Real-World Treatment Philosophies in Managing Atopic Dermatitis and Psoriasis: A Canadian Dermatologist SurveyJennifer Beecker, Chih-Ho Hong, Mark G Kirchhof, et al.
Therapeutic Advances in Rare Disease|February 3, 2026
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trialsHenning Andersen, Jordi Díaz-Manera, Ozlem Goker-Alpan, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 15, 2026
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2Giselle Mosnaim, Sarbjit Saini, Mark Lebwohl, et al.
Pageof 4